Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions.

Hsieh AM, Polyakova O, Fu G, Chazen RS, MacMillan C, Witterick IJ, Ralhan R, Walfish PG.

Oncotarget. 2018 Apr 13;9(28):19767-19782. doi: 10.18632/oncotarget.24833. eCollection 2018 Apr 13.

2.

Letter to the Editor referring to the retracted publication entitled "Straticyte demonstrates prognostic value over oral epithelial dysplasia grade for oral potentially malignant lesion assessment" by Hwang et al.

Hwang JTK, Gu YR, Dickson BJ, Shen M, Ralhan R, Walfish PG, Mock D, Pritzker KPH.

Oral Oncol. 2018 May;80:103. doi: 10.1016/j.oraloncology.2018.03.012. Epub 2018 Mar 23. No abstract available.

PMID:
29580748
3.

RETRACTED: Straticyte demonstrates prognostic value over oral epithelial dysplasia grade for oral potentially malignant lesion assessment.

Hwang JTK, Gu YR, Dickson BJ, Shen M, Ralhan R, Walfish PG, Mock D, Pritzker KPH.

Oral Oncol. 2018 Feb;77:138. doi: 10.1016/j.oraloncology.2017.12.019. No abstract available.

PMID:
29362120
4.

RETRACTED: Straticyte demonstrates prognostic value over oral epithelial dysplasia grade for oral potentially malignant lesion assessment.

Hwang JTK, Gu YR, Dickson BJ, Shen M, Ralhan R, Walfish PG, Mock D, Pritzker KPH.

Oral Oncol. 2017 Sep;72:1-6. doi: 10.1016/j.oraloncology.2017.06.024. Epub 2017 Jun 29. Erratum in: Oral Oncol. 2018 Feb;77:138.

PMID:
28797444
5.
6.

Individualized five-year risk assessment for oral premalignant lesion progression to cancer.

Hwang JT, Gu YR, Shen M, Ralhan R, Walfish PG, Pritzker KP, Mock D.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Mar;123(3):374-381. doi: 10.1016/j.oooo.2016.11.004. Epub 2016 Nov 22.

PMID:
28110942
7.
8.

Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis.

Somasundaram RT, Kaur J, Leong I, MacMillan C, Witterick IJ, Walfish PG, Ralhan R.

BMC Cancer. 2016 Jul 16;16:486. doi: 10.1186/s12885-016-2507-7.

9.

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG.

Oncotarget. 2016 May 31;7(22):32318-28. doi: 10.18632/oncotarget.8698.

10.

ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.

Fu G, Somasundaram RT, Jessa F, Srivastava G, MacMillan C, Witterick I, Walfish PG, Ralhan R.

Oncotarget. 2016 Mar 29;7(13):17162-81. doi: 10.18632/oncotarget.7751.

11.

Nuclear heterogeneous nuclear ribonucleoprotein D is associated with poor prognosis and interactome analysis reveals its novel binding partners in oral cancer.

Kumar M, Matta A, Masui O, Srivastava G, Kaur J, Thakar A, Shukla NK, RoyChoudhury A, Sharma M, Walfish PG, Michael Siu KW, Chauhan SS, Ralhan R.

J Transl Med. 2015 Aug 30;13:285. doi: 10.1186/s12967-015-0637-3.

12.

Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy.

Srivastava G, Somasundaram RT, Walfish PG, Ralhan R.

PLoS One. 2015 Jul 24;10(7):e0133735. doi: 10.1371/journal.pone.0133735. eCollection 2015.

13.

Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application.

Ralhan R, Veyhl J, Chaker S, Assi J, Alyass A, Jeganathan A, Somasundaram RT, MacMillan C, Freeman J, Vescan AD, Witterick IJ, Walfish PG.

Thyroid. 2015 Nov;25(11):1224-34. doi: 10.1089/thy.2015.0114. Epub 2015 Aug 6.

PMID:
26131603
14.

Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.

Srivastava G, Matta A, Fu G, Somasundaram RT, Datti A, Walfish PG, Ralhan R.

Mol Oncol. 2015 Oct;9(8):1720-35. doi: 10.1016/j.molonc.2015.05.005. Epub 2015 May 21.

15.

Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer.

Chauhan SS, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A, Assi J, Leong I, MacMillan C, Witterick I, Colgan TJ, Shukla NK, Thakar A, Sharma MC, Siu KW, Walfish PG, Ralhan R.

Oncogenesis. 2015 Apr 20;4:e147. doi: 10.1038/oncsis.2015.7.

16.

Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.

Orlov S, Salari F, Kashat L, Freeman JL, Vescan A, Witterick IJ, Walfish PG.

Endocrine. 2015 Sep;50(1):130-7. doi: 10.1007/s12020-015-0575-0. Epub 2015 Mar 20.

PMID:
25792004
17.

Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.

Orlov S, Salari F, Kashat L, Walfish PG.

J Clin Endocrinol Metab. 2015 May;100(5):1738-41. doi: 10.1210/jc.2014-4560. Epub 2015 Mar 9.

PMID:
25751110
18.

Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.

Assi J, Srivastava G, Matta A, MacMillan C, Ralhan R, Walfish PG.

PLoS One. 2015 Feb 19;10(2):e0107586. doi: 10.1371/journal.pone.0107586. eCollection 2015.

19.

Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.

Kumar M, Srivastava G, Kaur J, Assi J, Alyass A, Leong I, MacMillan C, Witterick I, Shukla NK, Thakar A, Duggal R, Roychoudhury A, Sharma MC, Walfish PG, Chauhan SS, Ralhan R.

J Transl Med. 2015 Jan 16;13:8. doi: 10.1186/s12967-014-0369-9.

20.

Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.

Srivastava G, Assi J, Kashat L, Matta A, Chang M, Walfish PG, Ralhan R.

BMC Cancer. 2014 Sep 29;14:726. doi: 10.1186/1471-2407-14-726.

21.

Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.

Hasan R, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, Chauhan SS, Ralhan R.

BMC Cancer. 2014 Jan 2;14:2. doi: 10.1186/1471-2407-14-2.

22.

Slug is a predictor of poor prognosis in esophageal squamous cell carcinoma patients.

Hasan MR, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, Chauhan SS, Ralhan R.

PLoS One. 2013 Dec 18;8(12):e82846. doi: 10.1371/journal.pone.0082846. eCollection 2013.

23.

The adenovirus 55 residue E1A protein is a transcriptional activator and binds the unliganded thyroid hormone receptor.

Arulsundaram VD, Webb P, Yousef AF, Pelka P, Fonseca GJ, Baxter JD, Walfish PG, Mymryk JS.

J Gen Virol. 2014 Jan;95(Pt 1):142-52. doi: 10.1099/vir.0.056838-0. Epub 2013 Oct 17.

24.

S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.

Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R.

Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8.

25.

Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.

Assi J, Srivastava G, Matta A, Chang MC, Walfish PG, Ralhan R.

PLoS One. 2013 Sep 13;8(9):e74437. doi: 10.1371/journal.pone.0074437. eCollection 2013.

26.

Clinical significance of altered expression of ╬▓-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression.

Kaur J, Sawhney M, DattaGupta S, Shukla NK, Srivastava A, Walfish PG, Ralhan R.

PLoS One. 2013 Jun 28;8(6):e67361. doi: 10.1371/journal.pone.0067361. Print 2013.

27.

Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.

Chaker S, Kashat L, Voisin S, Kaur J, Kak I, MacMillan C, Ozcelik H, Siu KW, Ralhan R, Walfish PG.

Proteomics. 2013 Mar;13(5):771-87. doi: 10.1002/pmic.201200356.

PMID:
23319340
28.

Iodine nutrition during pregnancy in Toronto, Canada.

Katz PM, Leung AM, Braverman LE, Pearce EN, Tomlinson G, He X, Vertes J, Okun N, Walfish PG, Feig DS.

Endocr Pract. 2013 Mar-Apr;19(2):206-11. doi: 10.4158/EP12193.OR.

29.

Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.

Kunavisarut T, Kak I, Macmillan C, Ralhan R, Walfish PG.

BMC Cancer. 2012 Nov 15;12:523. doi: 10.1186/1471-2407-12-523.

30.

Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.

Chaker S, Kak I, MacMillan C, Ralhan R, Walfish PG.

Thyroid. 2013 Feb;23(2):201-8. doi: 10.1089/thy.2012.0405.

PMID:
23148625
31.

An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.

He HC, Kashat L, Kak I, Kunavisarut T, Gundelach R, Kim D, So AK, MacMillan C, Freeman JL, Ralhan R, Walfish PG.

PLoS One. 2012;7(9):e42893. doi: 10.1371/journal.pone.0042893. Epub 2012 Sep 25.

32.

Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.

So AK, Kaur J, Kak I, Assi J, MacMillan C, Ralhan R, Walfish PG.

PLoS One. 2012;7(7):e40956. doi: 10.1371/journal.pone.0040956. Epub 2012 Jul 23.

33.

Radioiodine ablation in low-risk thyroid cancer.

Orlov S, Freeman JL, Walfish PG.

N Engl J Med. 2012 Aug 16;367(7):672; author reply 673-5. doi: 10.1056/NEJMc1206712. No abstract available.

PMID:
22894582
34.

Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence.

Yip J, Orlov S, Orlov D, Vaisman A, Hernández KG, Etarsky D, Kak I, Parvinnejad N, Freeman JL, Walfish PG.

Head Neck. 2013 Apr;35(4):592-8. doi: 10.1002/hed.23047. Epub 2012 Jun 23.

PMID:
22730192
35.

Stimulated thyroglobulin and neck ultrasonography facilitates postsurgical radioactive iodine remnant ablation selection in patients with low-risk well-differentiated thyroid carcinoma.

Gomez Hernandez K, Etarsky D, Orlov S, Walfish PG.

Thyroid. 2012 Jul;22(7):760-1. doi: 10.1089/thy.2011.0453. Epub 2012 Jun 4. No abstract available.

PMID:
22663549
36.

Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.

Ralhan R, He HC, So AK, Tripathi SC, Kumar M, Hasan MR, Kaur J, Kashat L, MacMillan C, Chauhan SS, Freeman JL, Walfish PG.

PLoS One. 2010 Nov 30;5(11):e14130. doi: 10.1371/journal.pone.0014130.

37.

Thyroid pathophysiology: reflections on physician-scientist careers in thyroidology.

Walfish PG.

Thyroid. 2010 Nov;20(11):1201-4. doi: 10.1089/thy.2010.1661. No abstract available.

PMID:
21062192
38.

Secretome-based identification and characterization of potential biomarkers in thyroid cancer.

Kashat L, So AK, Masui O, Wang XS, Cao J, Meng X, Macmillan C, Ailles LE, Siu KW, Ralhan R, Walfish PG.

J Proteome Res. 2010 Nov 5;9(11):5757-69. doi: 10.1021/pr100529t. Epub 2010 Oct 15.

PMID:
20873772
39.

EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.

Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL, Walfish PG.

BMC Cancer. 2010 Jun 25;10:331. doi: 10.1186/1471-2407-10-331.

40.

Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.

Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, Freeman JL, Walfish PG.

Head Neck. 2010 Jun;32(6):689-98. doi: 10.1002/hed.21371.

PMID:
20187016
41.

Thyroid cancer outcomes in Filipino patients.

Kus LH, Shah M, Eski S, Walfish PG, Freeman JL.

Arch Otolaryngol Head Neck Surg. 2010 Feb;136(2):138-42. doi: 10.1001/archoto.2009.206.

PMID:
20157058
42.

Identification of CCR4 and other essential thyroid hormone receptor co-activators by modified yeast synthetic genetic array analysis.

Govindan M, Meng X, Denis CL, Webb P, Baxter JD, Walfish PG.

Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19854-9. doi: 10.1073/pnas.0910134106. Epub 2009 Nov 10.

43.

The adenoviral E1A protein displaces corepressors and relieves gene repression by unliganded thyroid hormone receptors in vivo.

Sato Y, Ding A, Heimeier RA, Yousef AF, Mymryk JS, Walfish PG, Shi YB.

Cell Res. 2009 Jun;19(6):783-92. doi: 10.1038/cr.2009.55.

44.

Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma.

Orlov S, Orlov D, Shaytzag M, Dowar M, Tabatabaie V, Dwek P, Yip J, Hu C, Freeman JL, Walfish PG.

Head Neck. 2009 Jun;31(6):782-8. doi: 10.1002/hed.21020.

PMID:
19260133
45.

Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.

Sawka AM, Orlov S, Gelberg J, Stork B, Dowar M, Shaytzag M, Tabatabaie V, Freeman JL, Walfish PG.

Head Neck. 2008 Jun;30(6):693-700.

PMID:
18098308
46.

Mechanisms of action of the congenital diaphragmatic hernia-inducing teratogen nitrofen.

Noble BR, Babiuk RP, Clugston RD, Underhill TM, Sun H, Kawaguchi R, Walfish PG, Blomhoff R, Gundersen TE, Greer JJ.

Am J Physiol Lung Cell Mol Physiol. 2007 Oct;293(4):L1079-87. Epub 2007 Aug 17.

47.

Extrathyroidal extension in well-differentiated thyroid cancer: macroscopic vs microscopic as a predictor of outcome.

Hu A, Clark J, Payne RJ, Eski S, Walfish PG, Freeman JL.

Arch Otolaryngol Head Neck Surg. 2007 Jul;133(7):644-9.

PMID:
17638775
48.

Thyroid hormone response element organization dictates the composition of active receptor.

Velasco LF, Togashi M, Walfish PG, Pessanha RP, Moura FN, Barra GB, Nguyen P, Rebong R, Yuan C, Simeoni LA, Ribeiro RC, Baxter JD, Webb P, Neves FA.

J Biol Chem. 2007 Apr 27;282(17):12458-66. Epub 2007 Feb 20.

49.

Transient neonatal hypothyroidism is associated with elevated serum anti-thyroglobulin antibody levels in newborns and their mothers.

Ordookhani A, Mirmiran P, Walfish PG, Azizi F.

J Pediatr. 2007 Mar;150(3):315-7, 317.e2.

PMID:
17307555
50.

Corepressor/coactivator paradox: potential constitutive coactivation by corepressor splice variants.

Meng X, Arulsundaram VD, Yousef AF, Webb P, Baxter JD, Mymryk JS, Walfish PG.

Nucl Recept Signal. 2006 Oct 30;4:e022.

Supplemental Content

Loading ...
Support Center